Survey
Two Week Delay Survey on Severe hypertriglyceridemia (sHTG) October 2025
Ticker(s): ARWR, IONSThe survey results include 20 endocrinologists actively managing patients with severe hypertriglyceridemia (sHTG).
How many patients with severe hypertriglyceridemia (sHTG) do you personally manage?
Are you knowledgeable about the data for Tryngolza (olezarsen) and plozasiran?
- Yes
- No
How often do you meet with your sHTG patients? Select one.
- Quarterly
- Bi-annually
- Annually
- Something else, please specify
What percentage (%) of your sHTG patients have had a prior acute pancreatitis (AP) event?
What percentage (%) of your sHTG patients are currently receiving standard of care triglyceride (TG) lowering therapy?
What percentage (%) of your sHTG patients currently receiving standard of care TG lowering therapy, would do well with additional TG lowering agents?
To what percentage (%) of sHTG patients with a prior AP event would you offer an APOC3 silencing drug (Tryngolza (olezarsen) or plozasiran), if it were available today?
To what percentage of sHTG patients without a prior AP event would you offer an APOC3 silencing drug (Tryngolza (olezarsen) or plozasiran), if it were available today?
What is the primary reason a sHTG patient with a prior AP event would not receive an APOC3 silencing drug? Select one.
- Safety/tolerability concerns on glycemic control
- Payor restrictions on reimbursement
- Inconvenience of chronic injections
- Feel well-managed by existing therapies, lifestyle modifications
- Something else, please specify
What is the primary reason a sHTG patient without a prior AP event would not receive an APOC3 silencing drug? Select one.
- Safety/tolerability concerns on glycemic control
- Payor restrictions on reimbursement
- Inconvenience of chronic injections
- Feel well-managed by existing therapies, lifestyle modifications
- Something else, please specify
To what percentage (%) of sHTG patients with a prior AP event would you offer an APOC3 silencing drug in the first 12 months, if it were available today?
To what percentage (%) of sHTG patients without a prior AP event would you offer an APOC3 silencing drug in the first 12 months, if it were available today?
Would you reach out proactively to sHTG patients with a prior AP event to offer an APOC3 silencing drug, if it were available today?
- Yes
- No
- Other, specify:
Would you reach out proactively to sHTG patients without a prior AP event to offer an APOC3 silencing drug, if it were available today?
- Yes
- No
- Other, specify:
Between the two APOC3 silencing drugs, what would be your split of use assuming both are approved with similar safety/tolerability and efficacy? Must sum to 100%.
- Tryngolza(olezarsen)
- Plozasiran
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
